Country: United States
Language: English
Source: NLM (National Library of Medicine)
CARVEDILOL (UNII: 0K47UL67F2) (CARVEDILOL - UNII:0K47UL67F2)
REMEDYREPACK INC.
CARVEDILOL
CARVEDILOL 3.125 mg
ORAL
PRESCRIPTION DRUG
Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4) and Clinical Studies ( 14.1) ]. Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2) ]. Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3, 14.4)] . It can be used alone or in combination with other antihyper
Carvedilol Tablets USP, 3.125 mg are white to off-white, round, biconvex, film-coated tablets debossed with 'Z' on one side and '1' on other side and are supplied as follows: NDC: 70518-0582-00 NDC: 70518-0582-01 PACKAGING: 360 in 1 BOTTLE PLASTIC PACKAGING: 30 in 1 BLISTER PACK Storage: Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762
Abbreviated New Drug Application
CARVEDILOL- CARVEDILOL TABLET, FILM COATED REMEDYREPACK INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CARVEDILOL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CARVEDILOL TABLETS. CARVEDILOL TABLETS, FOR ORAL USE. INITIAL U.S. APPROVAL: 1995 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2) hypertension( 1.3) DOSAGE AND ADMINISTRATION Take with food. Individualize dosage and monitor during up-titration. ( 2) Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated. ( 2.1) Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily after intervals of 3 to 10 days. A lower starting dose or slower titration may be used.( 2.2) Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks.( 2.3) DOSAGE FORMS AND STRENGTHS Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg ( 3) CONTRAINDICATIONS Bronchial asthma or related bronchospastic conditions. ( 4) Second- or third-degree AV block. ( 4) Sick sinus syndrome. ( 4) Severe bradycardia (unless permanent pacemaker in place). ( 4) Patients in cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy. ( 4) Severe hepatic impairment ( 2.4, 4) History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. ( 4) WARNINGS AND PRECAUTIONS Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptl Read the complete document